Manager TitleAgeSince
President 61 31/05/2023
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/12/2020
Date Insider Type Main position Quantity % Market Cap.
31/05/23Issuer sale

Chief Operating Officer

247,717 0.6309%
31/05/23
MPM BioImpact LLC
OthersCompany 7,529,946 19.1788%
31/05/23Issuer sale

Chairman

51,482 0.1311%
Change 5-day change 1-year change 3-year change Capi.($)
-5.73%-15.43% - - 58.11M
+1.08%+7.56%+4.01%+9.84% 49.92B
+0.54%-1.16%+419.20%+626.68% 40.23B
+0.32%+7.46%+27.85%-4.58% 34.55B
+4.62%+7.27%+29.08%+64.22% 33.09B
-4.19%+6.03%+3.76%+32.17% 27.51B
-1.54%+2.54% - - 17.05B
+0.25%+4.44%+75.11%+138.67% 15.92B
-0.95%+0.76%+13.97%+21.59% 13.86B
+2.35%+4.05%+100.96%+101.05% 13.52B
Average -0.40%+5.72%+84.24%+123.71% 27.3B
Weighted average by Cap. +0.35%+6.43%+95.57%+141.85%
Logo TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. The Company's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The Company completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company's TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.
Employees
58
  1. Stock Market
  2. Stocks
  3. TCRR Stock